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Introduction
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is 
an inflammatory biomarker involved in atherosclerosis 
and directly associated with cardiovascular disease 
(CVD). It is a calcium-independent lipase that belongs 
to the superfamily of phospholipases A2 (PLA2) 
(1,2). It is produced mainly by inflammatory cells 
and circulates in the plasma linked to lipoproteins, 
preferentially low-density lipoprotein (LDL) (3). 
This enzyme has pro-inflammatory properties, since 
it hydrolyzes oxidized phospholipids thus releasing 
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Abstract
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker involved in 
atherosclerosis and cardiovascular disease (CVD). Iron stores may modify Lp-PLA2 as higher activity levels were 
observed in patients with primary iron overload (IO). 
Aim: to evaluate the changes of Lp-PLA2 activity and other atherosclerosis markers in patients with primary IO 
after iron depletion.
Materials and Methods: The study initially included 20 male patients with primary IO, defined by liver histology, 
from which 7 were lost during follow-up and 13 completed the study (mean follow-up duration: 24±6 months). 
Phlebotomy treatment consisted in the removal of 1 unit of blood weekly or biweekly. We recorded traditional 
cardiovascular risk factors, high sensitivity C-reactive protein (hsCRP), and Lp-PLA2 activity. Longitudinal 
differences were tested by paired T or Wilcoxon tests. Linear regression was used to evaluate the relationship 
between changes in ferritin and in Lp-PLA2.
Results: HFE mutations were present in 77% of the patients. Besides ferritin concentration (-74%), ALT (-11%) 
and Lp-PLA2 activities (-14%) were reduced after iron depletion (all p<0.05). Linear regression showed that 
changes in ferritin levels explained a 60% of the variability in the changes of Lp-PLA2 activity (B=0.80, p=0.008, 
R2= 0.60). 
Conclusions: Treatment by phlebotomy significantly reduced the levels of Lp-PLA2 activity besides its expected 
effects in liver markers. The implications of iron depletion for the reduction of CVD risk remain to be studied. 
Keywords: iron overload, phlebotomy, Lp-PLA2, hsCRP
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lysophosphatidylcholine and oxidized free fatty 
acids. These compounds are known to promote 
vascular inflammation and endothelial dysfunction 
(3). Moreover, high levels of Lp-PLA2 are present 
in inflamed, rupture-prone plaques, and it appears 
that Lp-PLA2 is released from these plaques into the 
circulation (4). The activity levels of Lp-PLA2 were 
associated with incident CVD and with increasing 
ferritin levels in an observational study. Then, a link 
between iron stores, oxidative stress and Lp-PLA2 was 
suggested (5). In the cross-sectional analysis of our 
study (6), Lp-PLA2 was found increased in patients 
with primary iron overload (IO) due to hereditary 
hemochromatosis. Moreover, Lp-PLA2 activity was also 
correlated with ferritin concentration independently 
of body mass index (BMI), apolipoprotein B and 
other confounders (6). The present analysis shows 
the longitudinal results of the study, which aimed to 
evaluate the changes of Lp-PLA2 activity and other 
atherosclerosis markers in patients with primary IO 
after iron depletion.
Materials and Methods 
Subjects
The patients in this study are the ones who achieved 
the ferritin concentration treatment target after iron 
depletion treatment by phlebotomy (mean follow-up 
duration: 24±6 months) (6). Phlebotomy treatment 
consisted in the removal of 1 unit (450 to 500 mL) 
of blood weekly or biweekly until achieving a goal 
of serum ferritin between 30 and 50 µg/L. From the 
initial 20 male patients with primary IO, defined by 
liver histology, 13 completed the study. There were 
no significant differences in the main clinical and 
biochemical characteristics between these 13 and the 
initial 20 patients. All participants were adult males 
(>18 years) The present study was carried out in 
accordance with the Declaration of Helsinki and the 
protocol was approved by the Ethics Review Board 
from Buenos Aires Italian Hospital and from the 
Faculty of Pharmacy and Biochemistry, University of 
Buenos Aires. 
Clinical and Biochemical Parameters
Blood samples were drawn after a 12h fast. Whole 
blood and serum aliquots were both stored at 4º 
and -70º C. Complete blood count, levels of iron, 
transferrin, ferritin, glucose, urea, creatinine, total 
bilirubin, apolipoproteins and ferritin, as well as 
the activities of liver enzymes were determined by 
automatized assays. C reactive protein was measured 
by a high sensitivity assay (hsCRP) (Roche Diagnostics, 
Mannheim, Germany). Measurement of Lp-PLA2 
activity was performed by an in-house radiometric 
assay as previously reported (6). Impaired fasting 
glucose was defined according to the American 
Diabetes Association criteria (7).
Genotyping 
The HFE gene mutations were studied by PCR-RFLP 
as described previously (8). The genotypes were 
assigned according to the patterns observed with a UV 
transilluminator.
Statistical Analysis
Distribution of all variables was analyzed using the 
Shapiro-Wilks test. Mean ± standard deviation (SD) 
or median (interquartile range) were used to describe 
normally or skewed distributed variables, respectively. 
The differences in qualitative variables were assessed 
by McNemar test. Longitudinal differences were 
tested by paired T test or Wilcoxon test according to 
data distribution. Linear regression was employed to 
assess the relationship between changes in ferritin and 
Lp-PLA2. Tests were considered statistically significant 
at p <0.05. The statistical software employed were 
INFOSTAT (Group INFOSTAT, Córdoba, Argentina) and 
SPSS 19.0 (Chicago, Illinois, USA).
Results
HFE mutations were present in 77% of the patients. 
Out of these, four presented HFE-C282Y homozygosis, 
two H63D homozygosis and one C282Y/H63D double 
heterozygosis. At baseline, 5 of the patients were in 
an advanced phase of treatment (ferritin <300µg/L). 
Among the others, two patients showed ferritin 
levels >1000 µg/L. General clinical and biochemical 
characteristics are shown in table I.
Mean age was 51 ± 12 years and mean BMI: 29 ± 4 kg/
m2. Impaired fasting glucose was present in 65% and 
50%, at baseline and post-phlebotomy evaluations, 
respectively. However, no significant differences 
in glucose levels were observed during treatment. 
Similarly, at baseline 23% presented hsCRP > 2 mg/L, 
while post-phlebotomy no patient showed elevated 
hsCRP (p = 0.111). 
Among liver function markers, only alanine amino 
transferase activity was significantly reduced by 
phlebotomy treatment [pre: 35 (29-45) vs. post: 31 
(22-33) U/L; paired differences (95 CI): -10 [(-35) – 
(-2)] U/L, p=0.02].
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Table 1. Differences between pre and post phlebotomy treatment in patients with primary iron overload (n = 13).
Pre Post Differences (IC 95%) P
Inf. Sup.
Iron (µg/dL) 146 ± 50 151 ± 60 -40.5 26.5 0.642
TSat (%) 57 ± 24 58 ± 32 -16.4 8.8 0.508
Ferritin (µg/l) 284 (146 - 691) 74 (47 – 381) 58.6 1312.1 <0.001
Glucose (mg/dl) 97 ± 22 87 (78 – 114) -25.9 10.5 0.754
TG (mg/dl) 142 (101 - 205) 150 ± 71 -14.6 57.4 0.220
TC (mg/dl) 178 ± 39 179 ± 27 -32.2 29.3 0.919
HDL-c (mg/dl) 42 ± 10 44 ± 9 -6.6 2.6 0.364
LDL-c (mg/dl) 116 ± 36 110 (85 – 141) -31.9 33.8 0.952
APO A-1 (mg/dl) 136 ± 21 127 ± 11 -8.8 18.3 0.442
APO B (mg/dl) 79 ± 22 76 ± 23 -16.4 14.4 0.886
hsCRP (mg/l) 1.0 (0.5 – 2.0) 0,7 ± 0,5 -0.04 2.5 0.130
TSat, transferrin saturation; TG, triglycerides; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density 
lipoprotein; apo, apolipoprotein; hsCRP, high sensitive C reactive protein. Data are shown as mean ± SD or median 
(interquartile range) according to data distribution.
Lp-PLA2, lipoprotein associated-phospholipase A2.
Fig 1. Activity of lipoprotein associated-phospholipase A2 (Lp-PLA2) in patients with IO (n = 13), both pre and 
post phlebotomy treatment. p <0.05.
The changes induced by phlebotomy treatment 
are shown in Table I. No statistically significant 
differences were observed in glucose or lipid 
metabolism parameters. Conversely, Lp-PLA2 activity 
was significantly reduced post-phlebotomy (Figure 1).
Attesting for the close relationship between iron stores 
and Lp-PLA2 activity, linear regression tests showed 
that changes in ferritin levels during treatment 
explained a 60% of the variability in the changes of 
Lp-PLA2 activity (B=0.80, p=0.008, R2= 0.60). 
Discussion
The present study shows that Lp-PLA2 activity 
decreased following iron depletion by phlebotomy 
treatment in patients with primary IO. In addition, as 
expected ALT activity was reduced showing an impact 
of phlebotomy over the indicators of liver function 
which was not followed by changes in plasma lipids. 
Tsimikas et al. showed that LDL-C, male gender and 
ferritin concentration were significant independent 
predictors of Lp-PLA2 activity in 765 middle aged-
adults (5). Such results agree with a role of iron 
in atherosclerosis through Lp-PLA2. In line with 
this hypothesis, Zacharsky et al. performed an iron 
reduction trial in subjects with peripheral arterial 
disease, the FeAST trial (9). While no positive effect 
was observed in the iron reduction arm, an interesting 
interaction between age and iron reduction was 
observed. Indeed, in a sub-analysis of the trial, younger 
patients assigned to iron reduction showed a lower 
risk of CVD events than the control group (10). In 
addition, and as a possible explanation to the results, 
inflammatory markers, such as interleukin (IL)-6 
and hsCRP were closely related to iron levels (11). 
Unfortunately, Lp-PLA2 activity was not measured in 
the FeAST trial. 
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In our cross-sectional analysis, we observed that male 
patients with primary IO displayed increased Lp-PLA2 
activity, partially explained by high ferritin levels. We 
extend those results by showing that iron reduction 
was sufficient to decrease plasma Lp-PLA2 activity. 
Since Lp-PLA2 is not only a marker of coronary 
disease, but an important player in the development 
of advanced atherosclerosis plaques, the prospect 
of iron reduction to reduce the activity of Lp-PLA2 
and cardiovascular risk should be explored in future 
studies. 
In conclusion, Lp-PLA2 levels decreased with iron 
depletion by phlebotomy, in patients with primary IO. 
Such result may bring support to iron depletion as an 
option for the reduction of CVD risk. Future studies 
in patients without overt IO are necessary to confirm 
such association.
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